期刊
PHARMACOGENOMICS JOURNAL
卷 13, 期 3, 页码 209-217出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2012.2
关键词
ADR; colorectal cancer; FOLFOX; GWAS; 5-fluorouracil
资金
- Fondo de Investigacion Sanitatia/FEDER [06/1384, CP06/0267, 06/1712, 08/0024, 08/1276, PI08-1359, PI08-1635, PS09/02368]
- Instituto de Salud Carlos III (Accion Transversal de Cancer)
- Xunta de Galicia [PGIDT08CSA005208PR, PGIDIT07P-XIB9101209PR]
- Ministerio de Ciencia e Innovacion [SAF 07-64873, SAF 2010-19273]
- Fundacion Privada Olga Torres
- Fundacion Barrie de la Maza (Programa DIANA)
- Asociacion Espanola contra el Cancer (Fundacion Cientifica y Junta de Barcelona)
- Fundacion Mutua Madrilena (LFLA)
- Fundacion Ramon Areces (LFLA)
- Agencia d'Informacio Avaluacioi Qualitat en Salut [209/12/2009]
- FP7 CHIBCHA Consortium
- Instituto de Salud Carlos III
- Fondo de Investigacion Sanitaria [PS09/02368, CP 03-0070]
- Wellcome Trust [075491/Z/04]
- Cancer Research UK [16459] Funding Source: researchfish
The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据